Navigation Links
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
Date:5/7/2008

tive household survey, which used a lay-administered diagnostic interview to assess a wide range of DSM-IV disorders. ADHD is a neurobiological disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

For further information please contact:

Porter Novelli for Shire

Sherry Goldberg

212.601.8279

917.923.4010 (mobile)

sherry.goldberg@porternovelli.com

Michelle Park

212.601.8248

212.729.4577 (mobile)

michelle.park@porternovelli.com

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
3. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
4. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
5. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
6. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
7. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
8. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
9. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), ... that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... The terms of the acquisition were not disclosed. ... company providing a wide range of sleep, mobility, and respiratory ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... REMICADE Therapy is More Likely to Induce Steroid-Free Remission ... ... Data presented for the first time,from the Phase 3b Study ... may provide new insights into,the approach to care of patients with ...
... More than 60 percent of moderate to severe ... achieved endoscopic remission at Week 10,in data from ... College,of Gastroenterology (ACG) Annual Scientific Meeting, ORLANDO, ... from a,large, prospective study investigating endoscopic improvement in ...
Cached Medicine Technology:New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... In a review published in the April issue ... of The Feinstein Institute for Medical Research, says it,s ... community,s approach to treating sepsis, which kills ... , Sepsis occurs when molecules released into the bloodstream ... the body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... , WASHINGTON , Jan. 15 ... with 22 national organizations, attended the first consortium meeting ... initiative to improve lupus diagnosis, treatment, and management among ... Rheumatology offices in Atlanta, Georgia from January ...
... FRANCISCO , Jan. 15 A Good Idea , a ... San Francisco , plans to give $100,000 to Haiti ... Community Giving contest sponsored by JPMorgan Chase & Co. , "While ... Bay Area, we feel that it is of the utmost importance to contribute ...
... , SANTA BARBARA, Calif. , Jan. 15 ... connecting essential micronutrients, especially vitamin A, with infants and children ... a disaster relief agency, Vitamin Angels has responded to ... Haiti , by shipping over 1 million children,s multivitamins. After ...
... , PHOENIX , Jan. 15 ... rice bran (SRB) nutrient research and technology, today announced a 17% ... to improve the company,s cost structure. The reduction, which is anticipated ... impact the workforce at Irgovel, NutraCea,s Brazilian subsidiary. , W. ...
... , OCEANSIDE, Calif. , Jan. 15 ... organizations that work with teens are tirelessly launching grassroots efforts to ... In many cities, the efforts are led by teens themselves. , ... cannot change the world.  But the people who see it can ...
... , Jan. 15 The March of Dimes has ... mothers and babies in Haiti imperiled by the devastating ... concerned about the thousands of pregnant women and moms caring for ... Dr. Jennifer L. Howse , president of the March of ...
Cached Medicine News:Health News:Lupus Foundation of America Collaborates with Federal Agencies and the U.S. Surgeon General's Office to Expand Medical Education on Lupus 2Health News:Lupus Foundation of America Collaborates with Federal Agencies and the U.S. Surgeon General's Office to Expand Medical Education on Lupus 3Health News:San Francisco Charity A GOOD IDEA to Give $100,000 to Haiti Victims Upon Winning Nationwide Charity Program 2Health News:Vitamin Angels Responds to Haiti Disaster 2Health News:NutraCea Announces Reduction in Workforce in U.S. Operations 2Health News:Movie Turns Into a Growing Movement to Reach Hurting Teens. 2Health News:Movie Turns Into a Growing Movement to Reach Hurting Teens. 3Health News:Movie Turns Into a Growing Movement to Reach Hurting Teens. 4Health News:Movie Turns Into a Growing Movement to Reach Hurting Teens. 5Health News:March of Dimes Supports Urgent Needs of Mothers and Babies in Haiti Earthquake 2
... grafting or creation of a vascular access, ... is of the utmost importance in many ... for those seeking a high-precision tunneling instrument. ... risk of twisting or kinking for more ...
... Stretch Vascular Grafts have met the ... procedures. Recognized for exceptional performance and ... of renowned surgeons worldwide. These grafts ... the spread of infection, and ensure ...
... Today's evolving techniques for vascular surgery, ... require that new, specialized types of graft ... strong, inert and biocompatible, but also available ... vascular access. GORE-TEX Vascular Graft has long ...
... INTERING Vascular Graft, the newest vascular graft ... a leader in vascular surgical products for ... by reducing kinking and compression problems ... new graft provides all of the benefits ...
Medicine Products: